申请人:Ciba-Geigy Corp
公开号:US05312914A1
公开(公告)日:1994-05-17
The invention relates to a novel process for the manufacture of 4-acetoxy-3-hydroxyethyl-azetidinone of the formula ##STR1## especially 4(R)-acetoxy-3(R)-(1'(R)-hydroxyethyl)-2-azetidinone, from enantiomerically pure compounds of the formula ##STR2## in which R.sup.1 represents lower alkyl and Z.sup.1 represents amino, arylmethylamino, acylamino or azido, by reduction of the C.dbd.C double bond and optionally of the arylmethylamino or azido group with hydrogen, epimerization, opening of the lactone ring, cyclisation to the .beta.-lactam, optionally after hydrolysis of the acylamino group, and oxidative decarboxylation of the original lactone carboxy group in the presence of an acetate-yielding agent. Compounds of the formula I can be used as starting materials for the manufacture of .beta.-lactam antibiotics. The invention also relates to novel intermediates and starting materials.
该发明涉及一种新型制备4-乙酰氧基-3-羟基乙基-吖啶酮的方法,其化学式为##STR1## 尤其是4(R)-乙酰氧基-3(R)-(1'(R)-羟乙基)-2-吖啶酮,从对映纯化合物的化学式##STR2## 中制备,其中R.sup.1代表较低的烷基,Z.sup.1代表氨基、芳基甲基氨基、酰胺基或偶氮基,通过氢气还原C.dbd.C双键和可选地还原芳基甲基氨基或偶氮基团,对映异构化,打开内酯环,环化成β-内酰胺,在存在乙酸产生剂的情况下,可选地在水解酰胺基团后,对原始内酯羧基进行氧化脱羧。化合物I的中间体和起始物也可用作β-内酰胺类抗生素的制备起始物。